On this page

What happened

In a July 2, 2026 warning letter to Good Stuff Cacao, FDA described disease-treatment and prevention claims on the seller’s website and labels. Green-tea claims referred to Alzheimer’s disease, Parkinson’s disease and anxiety; the letter also addressed goji berries, cacao and honey. FDA said these intended uses placed the products within the U.S. drug framework and that the products lacked approval for the cited uses. The letter followed a website review in April.

Why it matters

The regulatory question is what a seller represents a product as doing. A familiar food or botanical does not acquire proven disease-treatment efficacy through a label claim. For readers evaluating brain-health marketing, the letter illustrates why a mechanistic finding or a general nutritional association must not be promoted as evidence that a particular retail product treats a neurological disorder. The notice itself does not compare green tea with a treatment or measure anyone’s cognition.

Scope and limitations

FDA requested a response within 15 working days of receipt and warned that inadequate correction could lead to enforcement. That request is not a report that a court imposed a penalty or that FDA had completed every possible enforcement step. The letter concerns a named business and claims under U.S. law; it is neither a worldwide prohibition on drinking green tea nor a determination of Turkish legal status. Its value is as a documented marketing-compliance example, with the quoted claims attributed to the seller.

This sourced news summary and translation were prepared with AI assistance. Source links, the news date and research limitations are disclosed; this is not a claim of independent medical expert review. News production method.

Sources

Research news is not medical advice or a recommendation to use a substance. Read findings in the context of the study design, participants and limitations. Editorial standards.

← All news